Molecular basis for targeting Caveolin-1 in multiple myeloma therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Multiple myeloma (MM) is a plasma cell cancer known for frequent relapse and treatment resistance.
• Caveolin-1 (Cav-1), a protein forming plasma membrane caveolae, influences cell signaling, metabolism, autophagy, and bone marrow microenvironment interactions.

Purpose of the Study:

• To review the role of Cav-1 in MM progression and resistance to therapy.
• To summarize preclinical strategies targeting Cav-1 and discuss challenges for clinical translation.

Main Methods:

• Literature review of studies on Cav-1 in multiple myeloma.
• Analysis of preclinical approaches including small molecules, peptides, RNA-based methods, and CRISPR.
• Discussion of combination therapies and challenges in clinical translation.

Main Results:

• Cav-1 plays a significant role in MM cell survival, adhesion, and communication within the bone marrow microenvironment.
• Preclinical strategies show potential for targeting Cav-1, including combination with proteasome inhibitors.
• Challenges include the need for selective inhibitors and managing potential toxicity.

Conclusions:

• Cav-1 represents a context-dependent therapeutic vulnerability in MM.
• Targeting Cav-1 can restore drug sensitivity, reduce protective effects of the bone marrow microenvironment, and enhance anti-tumor immunity.
• Developing selective or tumor-targeted delivery mechanisms for Cav-1 inhibitors is crucial for effective combination treatments in resistant MM.